Remedica Ltd.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Remedica Ltd. - overview

Established

1980

Location

Limassol, -, Cyprus

Primary Industry

Pharmaceuticals

About

Founded in 1980 by Takis Pattichis and based in Limassol, Cyprus, Remedica Ltd. produces generic and over-the-counter pharmaceutical products and exports its products in more than 10 countries. In August 2016, Ascendis Health Limited acquired Remedica Ltd. for EUR 260 million.


As of 2021, the company employs more than 800 employees, has over 350 pharmaceutical products, and is led by its CEO Dr. Michael Neoptolemou. Remedica manufactures generic and over-the-counter pharmaceutical products such as antidepressants, antivirals, antibacterials, immunosuppressants, blocking agents, and anti-inflammatory tablets and capsules. The company has factories that produce pharmaceutical products for general use, penicillin derivatives, cefalosporins, and cancer treatment.


Current Investors

Ascendis Health Limited

Primary Industry

Pharmaceuticals

Sub Industries

Specialty Pharmaceuticals, Pharmaceutical Research & Development

Website

www.remedica.eu

Verticals

Manufacturing

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Remedica Ltd. - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
LP Direct, Trade SaleCompletedRemedica Ltd.-
Secondary BuyoutCompletedRemedica Ltd.-
Add-onCompletedRemedica Ltd.-

Displaying 1 - 3 of 3

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.